Novel Molecules To Treat Chronic Central Nervous System Toxoplasmosis

Area of Science:

• Infectious Diseases
• Parasitology
• Drug Discovery

Background:

• Toxoplasmosis poses a significant challenge for immunocompromised individuals, with current therapies often failing to eradicate chronic infections or prevent relapse.
• The latent bradyzoite stage of *Toxoplasma gondii* is particularly difficult to target, contributing to persistent infections and reactivation.
• Identifying novel therapeutic targets is crucial for developing more effective treatments for toxoplasmosis.

Purpose of the Study:

• To investigate the efficacy of targeting *Toxoplasma gondii* Calcium-Dependent Protein Kinase 1 (CDPK1) as a therapeutic strategy.
• To evaluate novel pyrazolopyrimidine inhibitors of CDPK1 for their potential to clear chronic toxoplasmosis and eliminate latent bradyzoites.
• To assess the in vitro and in vivo activity of CDPK1 inhibitors in a relevant animal model.

Main Methods:

• Utilized a mouse model of toxoplasmosis to evaluate therapeutic interventions.
• Synthesized and characterized pyrazolopyrimidine compounds designed to inhibit *Toxoplasma gondii* CDPK1.
• Assessed the efficacy of these inhibitors through in vitro assays and in vivo studies in infected mice.

Main Results:

• Pyrazolopyrimidine inhibitors targeting *Toxoplasma gondii* CDPK1 demonstrated significant activity.
• These compounds showed efficacy both in vitro and in vivo in the mouse model of toxoplasmosis.
• The study provides evidence for CDPK1 as a viable target for anti-toxoplasmosis drug development.

Conclusions:

• CDPK1 is a promising novel target for the development of new therapeutic agents against toxoplasmosis.
• Pyrazolopyrimidine inhibitors of CDPK1 offer a potential strategy for clearing chronic infections and preventing recrudescence in immunocompromised patients.
• Further research into CDPK1 inhibitors could lead to improved treatments for toxoplasmosis, particularly for vulnerable populations.